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Clinics and pathology 
Phenotype / cell stem origin 
Alveolar rhabdomyosarcoma (ARMS). 
Epidemiology 
Occurs in a small subset of ARMS cases (<5%). There 
are five reported cases. 
Pathology 
No information available. 
Cytogenetics 
Cytogenetics Morphological 
Of the five reported cases, cytogenetics was only 
performed on one case and demonstrated a normal 
karyotype. 
Cytogenetics Molecular 
Several of these cases were detected using fluorescence 
in situ hybridization analysis by the finding of PAX3 
rearrangement without evidence of a PAX3-FOXO1 
fusion or FOXO1 rearrangement. Other cases were 
detected by directly assaying cases with a PAX3-
NCOA1 fusion-specific RT-PCR assay. 
Genes involved and proteins 
Note 
A variant t(2;8)(q35;q13) translocation has been 












The NCOA2 gene (encoding another member of the 
p160 family of transcriptional coactivators) is located 
at 8q13 and involved in the variant t(2;8). 
Protein 
Transcription factor - paired box (PAX) family. 




Based on the cloned cDNA, there appears to be two 
possible scenarios for formation of fusion genes. In 
some cases, the translocation apparently breaks within 
PAX3 intron 6 and NCOA1 intron 12 (type 1), and in 
other cases the translocation breaks within PAX3 intron 
7 and NCOA1 intron 11 (type 2). 
Transcript 
The type 1 fusion transcript consists of the first six 
PAX3 exons fused to the last nine NCOA1 exons  
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Generation of chimeric genes by the 2;2 translocation in ARMS. The exons of the wild-type and fusion genes are shown as boxes above 
each map and the translocation breakpoint distributions are shown as line segments below the map of the wild-type genes. 
 
 
(from exon 13 onward) and the type 2 fusion transcript 
consists of the first seven PAX3 exons fused to the last 
ten NCOA1 exons (from exon 12 onward). 
Fusion Protein 
Description 
The type 1 fusion gene encodes a 894 amino acid 
fusion protein and the type 2 fusion gene encodes a 
1026 amino acid fusion protein. The fusion proteins 
encode novel transcription factors with the PAX3 DNA 
binding domain and the NCOA1 transcriptional 
activation domains. 
Oncogenesis 
Transcription dysregulation. At the cellular level there 
is evidence of alterations in control of growth, resulting 
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